Marathon effort to support cancer care

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

Oncologist Howard Hochster, MD, professor of medicine at New York University Cancer Institute, ran the 2008 New York City Marathon to benefit Team Continuum which provides immediate nonmedical support and assistance to cancer patients and their families.

Oncologist Howard Hochster, MD, professor of medicine at New York University Cancer Institute, ran the 2008 New York City Marathon to benefit Team Continuum which provides immediate nonmedical support and assistance to cancer patients and their families. Dr. Hochster (right) is pictured with fellow runner Geraldo Rivera (not the TV personality). Mr. Rivera’s 11-year-old daughter is a brain cancer patient and a Team Continuum grant recipient. Dr. Hochster and Mr. Rivera were among 400 runners supporting Team Continuum. The non-profit organization raised more than $5.5 million last year to fund their cancer care and support efforts.

The organization is currently enrolling runners for the April 20, 2009, Boston marathon. For more information, go to www.teamcontinuum.net.

Recent Videos
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
Related Content